I-Mab Strengthens Givastomig Intellectual Property Portfolio through Acquisition of Bridge Health

Acquisition provides I-Mab with upstream rights to CLDN18.2 parental antibody for use in bispecific and multi-specific applications Acquisition eliminates all royalty obligations and reduces future milestones for givastomig due to Bridge Health by I-Mab ROCKVILLE, Md., July 17, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (the Company), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced that it entered into a def ...